Oncotarget: Paradox breaker BRAF inhibitors in BRAF mutant colorectal cancer

August 25, 2020

OncotargetVolume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.

Resistance to BRAF inhibition in CRC arises in part through the generation and activation of RAF dimers resulting in MEK-ERK pathway reactivation.

The Oncotarget authors analyzed whether paradox breakers reduce pathway reactivation and so have enhanced potency compared with encorafenib in BRAF mutant CRC.

However, dose-response curves for encorafenib and PLX8394 were similar and there were no significant differences in the degree of pathway reactivation.

To their knowledge, these data represent the first comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC.

Dr. Gary W. Middleton from The Institute of Immunology and Immunotherapy at The University of Birmingham said, "Around 10% of patients with metastatic colorectal cancer (CRC) harbour a BRAF mutation."

Recently results of the BEACON CRC trial demonstrated an enhanced survival for chemo-refractory BRAF mutant CRC patients for the combination of the BRAF inhibitor encorafenib together with the EGFR inhibitor cetuximab and the MEK inhibitor binimetinib compared with the control group of cetuximab and irinotecan-based therapy.

The addition of EGFR and MEK inhibition to the BRAF inhibitor backbone is predicated on the activation of RAS observed following BRAF inhibition.

Encorafenib is a group 1 BRAF inhibitor that selectively inhibits active BRAF monomers.

This phenomenon causes pathway reactivation and resistance to BRAF inhibition in BRAF mutant cells and paradoxical pathway activation in BRAF wild-type cells.

PLX8394 is a paradox-breaker BRAF inhibitor that inhibits BRAF dimerization and which does not result in paradoxical activation in BRAF wild-type cells.

The Middleton Research Team concluded in their OncotargetResearch paper that they have shown that the strategy of using a paradox breaker BRAF inhibitor such as PLX8394 in order to reduce pathway reactivation through reduced RAF dimerization in BRAF mutant CRC is as effective as optimal group 1 inhibitors such as encorafenib.

The degree of pathway reactivation is similar likely due to the inability of PLX8394 to inhibit CRAF homodimer formation and the activation by PLX8394 of such dimers.

As with the continued clinical development of BRAF inhibition in BRAF mutant cancers, the activity of PLX8394 should be investigated as part of a combination with other drugs that limit pathway reactivation such as MEK and EGFR inhibitors.

However, the general strategy of targeting RAF dimerization in RAS/RAF mutant colorectal cancers is unlikely to qualitatively transform the outcomes with targeted therapies without appropriate attention to the unique biology of BRAF and KRAS mutant CRC.

The lack of confirmed objective responses in BRAF mutant CRC, in contradistinction to melanoma, to the RAF dimer inhibitor lifirafenib which inhibits all RAF isoforms as well as EGFR and KRAS supports this hypothesis.

Sign up for free Altmetric alerts about this article

DOI - https://doi.org/10.18632/oncotarget.27681

Full text - https://www.oncotarget.com/article/27681/text/

Correspondence to - Gary W. Middleton - G.Middleton@bham.ac.uk

Keywords - colorectal cancer, BRAF, paradox breaker, encorafenib, PLX8394

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud -https://soundcloud.com/oncotarget
Facebook -https://www.facebook.com/Oncotarget/
Twitter -https://twitter.com/oncotarget
LinkedIn -https://www.linkedin.com/company/oncotarget
Pinterest -https://www.pinterest.com/oncotarget/
Reddit -https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnlsMedia Contact
MEDIA@IMPACTJOURNALS.COM
18009220957x105

Impact Journals LLC

Related Colorectal Cancer Articles from Brightsurf:

Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

Read More: Colorectal Cancer News and Colorectal Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.